Lipella Pharmaceuticals Inc.

NasdaqCM:LIPO Stock Report

Market Cap: US$7.3m

Lipella Pharmaceuticals Management

Management criteria checks 3/4

Lipella Pharmaceuticals' CEO is Jon Kaufman, appointed in Jan 2005, has a tenure of 20.33 years. total yearly compensation is $277.30K, comprised of 84.1% salary and 15.9% bonuses, including company stock and options. directly owns 4.41% of the company’s shares, worth $319.64K. The average tenure of the management team and the board of directors is 15.2 years and 2.2 years respectively.

Key information

Jon Kaufman

Chief executive officer

US$277.3k

Total compensation

CEO salary percentage84.13%
CEO tenure20.3yrs
CEO ownership4.4%
Management average tenure15.2yrs
Board average tenure2.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jon Kaufman's remuneration changed compared to Lipella Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$5m

Dec 31 2024US$277kUS$233k

-US$5m

Sep 30 2024n/an/a

-US$4m

Jun 30 2024n/an/a

-US$4m

Mar 31 2024n/an/a

-US$5m

Dec 31 2023US$323kUS$204k

-US$5m

Sep 30 2023n/an/a

-US$4m

Jun 30 2023n/an/a

-US$4m

Mar 31 2023n/an/a

-US$3m

Dec 31 2022US$183kUS$183k

-US$3m

Sep 30 2022n/an/a

-US$3m

Jun 30 2022n/an/a

-US$2m

Mar 31 2022n/an/a

-US$2m

Dec 31 2021US$914kUS$183k

-US$2m

Dec 31 2020US$183kUS$183k

-US$62k

Compensation vs Market: Jon's total compensation ($USD277.30K) is below average for companies of similar size in the US market ($USD650.80K).

Compensation vs Earnings: Jon's compensation has been consistent with company performance over the past year.

CEO

Jon Kaufman (57 yo)

20.3yrs
Tenure
US$277,300
Compensation

Dr. Jonathan Kaufman, also known as Jon, PhD, MBA is Co-Founder, Chairman, CEO, President, Secretary & Treasurer of Lipella Pharmaceuticals Inc. since 2005. Dr. Kaufman was Co-Founder, Chairman, CEO & Pres...

Leadership Team

NamePositionTenureCompensationOwnership
Jonathan Kaufman
Co-Founder20.3yrsUS$277.30k4.41%
$ 319.6k
Michael Chancellor
Co-Founder20.3yrsUS$269.00k4.3%
$ 312.1k
Douglas Johnston
Chief Financial Officer2.5yrsUS$192.50k0%
$ 0
Michele Gruber
Director of Operations15.2yrsno data0%
$ 0
Janet Okonski
Director of Clinical Operations3.8yrsno datano data
Katie Johnston
Controllerno datano datano data
15.2yrs
Average Tenure
57yo
Average Age

Experienced Management: LIPO's management team is seasoned and experienced (15.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jonathan Kaufman
Co-Founder20.3yrsUS$277.30k4.41%
$ 319.6k
Michael Chancellor
Co-Founder17.3yrsUS$269.00k4.3%
$ 312.1k
Ryan Pruchnic
Independent Director3.7yrsUS$13.75k0%
$ 0
Michael Brennan
Member of Scientific Advisory Board2.2yrsno datano data
Byong Kim
Independent Director3.2yrsUS$13.75k0%
$ 0
Naoki Yoshimura
Independent Director & Member of Advisory Board3.7yrsUS$13.75k0%
$ 0
Alessandro Villa
Chair of the Scientific Advisory Board2.2yrsno datano data
Kamal Al-Eryani
Member of Scientific Advisory Board2.2yrsno datano data
Vidya Sankar
Member of Scientific Advisory Board2.2yrsno datano data
Herve Sroussi
Member of Scientific Advisory Board2.2yrsno datano data
Daniel Cohen
Independent Director2.2yrsUS$13.75k0%
$ 0
Lori Birder
Independent Director1.9yrsUS$13.75k0%
$ 0
2.2yrs
Average Tenure
59yo
Average Age

Experienced Board: LIPO's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/28 04:13
End of Day Share Price 2025/05/28 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lipella Pharmaceuticals Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason McCarthyMaxim Group